Overall prognosis is dependent on the extent of<unk>  dysfunction. Worse outcomes have been seen when echocardiography shows left ventricular wall thickness, poor systolic function and severe diastolic dysfunction. Light chain (AL-CM) Prognosis: For light-chain<unk>  early detection leads to best possibility of therapies prolonging the period of remission. Well treated light chain<unk>  has a 4 year survival rate of around 90%. In patients that undergo stem cell transplant the average survival time increases to 10 years. Staging systems have been developed to stratify severity of the disease, including the Mayo Biomarker Stage, which utilizes various biomarkers such as troponin I, troponin T, BNP, and NT-proBNP, and Free light chain concentrations. Familial (ATTRm-CM) Prognosis: Due to the extensive number of variables involved in this subtype, prognosis varies depending on the specific type of familial<unk> . Variables involve mutant vs wild type transthyretin mutation and age of onset of symptoms. In comparison to light chain<unk> , the familial subtype is slower to progress and has a more favorable prognosis. However, the Val 122lle mutation (most common cause of familial<unk>  has a 4 year survival rate of 16% with an average length of 26 months. A delay in recognition plays a major factor in this reduced survival rate.
Cardiac amyloidosis
Amyloid cardiomyopathy
Viral cardiomyopathy
Diabetic cardiomyopathy
HIV associated cardiomyopathy
Alcoholic cardiomyopathy
Coxsackievirus-induced cardiomyopathy
Dilated cardiomyopathy